Lupin’s partner ForDoz receives USFDA approval for doxorubicin hydrochloride liposome injection

Doxorubicin Hydrochloride Liposome Injection (RLD Doxil) had estimated annual sales of USD 42 million in the U.S. (IQVIA MAT May 2024)

Lupin divests US commercial women's health specialty business to Evofem

Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones

Lupin receives EIR from USFDA for its Dabhasa facility

The facility is a part of Lupin Manufacturing Solutions

Lupin receives tentative approval from USFDA for Empagliflozin, Linagliptin and Metformin Hydrochloride ER tablets

This product will be manufactured at Lupin’s Pithampur facility in India

Lupin receives EIR from US FDA for its Somerset manufacturing facility

The facility was inspected from May 7 to May 17, 2024

Lupin appoints Abdelaziz Toumi as CEO of its API CDMO subsidiary

Abdel has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma,

Lupin and Fuji sign agreement for commercialization of Nextstellis in Vietnam and Philippines

USFDA inspection of Lupin’s Nagpur injectable facility with zero 483 observations

Lupin completes acquisition of two brands from Sanofi in Europe and Canada

The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas

Lupin receives USFDA approval for travoprost ophthalmic solution

Travoprost Ophthalmic Solution USP, 0.004%, is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.